Julia M. Houthuijzen

Dr. Julia M. Houthuijzen


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2018 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
JHJulia M. Houthuijzen
Julia M. Houthuijzen
JJJos Jonkers
Jos Jonkers

12 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJulia M. Houthuijzen
Julia M. Houthuijzen
RBRoebi de Bruijn
Roebi de Bruijn
EBEline van der Burg
Eline van der Burg
ADAnne Paulien Drenth
Anne Paulien Drenth
EWEllen Wientjens
Ellen Wientjens
JJJos Jonkers
Jos Jonkers
Cancer-associated fibroblasts (CAFs) are abundantly present in the microenvironment of virtually all tumors and strongly impact tumor progression. Despite increasing insight into their function and heterogeneity, little is known regarding the origin of CAFs. Understanding the origin of CAF heterogeneity is needed to develop successful CAF-based targeted therapies. Through various transplantation studies in mice, we show that CAFs in both invasive lobular breast cancer and triple-negative breast cancer originate from mammary tissue-resident normal fibroblasts (NFs). Single-cell transcriptomics, in vivo and in vitro studies reveal the transition of CD26+ and CD26- NF populations into inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs), respectively. Functional co-culture experiments show that CD26+ NFs transition into pro-tumorigenic iCAFs which recruit myeloid cells in a CXCL12-dependent manner and enhance tumor cell invasion via matrix-metalloproteinase (MMP) activity. Together, our data suggest that CD26+ and CD26- NFs transform into distinct CAF subpopulations in mouse models of breast cancer.

1 December 2016 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
JHJulia M. Houthuijzen
Julia M. Houthuijzen
Increased energy intake can lead to obesity, which increases the risk for the development of diabetes and cancer. Free fatty acids regulate numerous cellular processes, like insulin secretion, inflammation, proliferation, and cell migration. Dysregulation of these cellular functions by increased lipid intake plays a significant role in the development of diseases like diabetes and cancer. Free fatty acid receptors 1 and 4 (FFAR1 and FFAR4) are two free fatty acid receptors under increasing investigation for their roles in diabetes and more recently also cancer. Both receptors bind medium- to long-chain, saturated and omega-3 unsaturated fatty acids. Increasing evidence shows that enhanced FFAR1 and FFAR4 signaling reduces diabetes symptoms but enhances tumor growth and migration of various cancer types like melanoma and prostate cancer. This review gives an overview of the role of FFAR1 and FFAR4 in diabetes and cancer and discusses their potential to function as targets for treatment.

9 August 2022 in Immunity
Verified
Journal Article
Closed access
JHJulia M. Houthuijzen
Julia M. Houthuijzen
KVKarin E de Visser
Karin E de Visser

28 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JHJulia M. Houthuijzen
Julia M. Houthuijzen
RBRoebi de Bruijn
Roebi de Bruijn
EBEline van der Burg
Eline van der Burg
ADAnne Paulien Drenth
Anne Paulien Drenth
EWEllen Wientjens
Ellen Wientjens
JJJos Jonkers
Jos Jonkers
Cancer-associated fibroblasts (CAFs) are abundantly present in the microenvironment of virtually all tumors and strongly impact tumor progression. Despite increasing insight into their function and heterogeneity, little is known regarding the origin of CAFs. Understanding the origin of CAF heterogeneity is needed to develop successful CAF-based targeted therapies. Through various transplantation studies in mice we determined that CAFs in both invasive lobular breast cancer and triple negative breast cancer originate from mammary tissue-resident normal fibroblasts (NFs). Single-cell transcriptomics, in vivo tracing and in vitro studies revealed the transition of CD26+ and CD26- NF populations into inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs), respectively. In vitro functional assays showed that CD26+ NFs transition into pro-tumorigenic iCAFs which recruit myeloid cells in a CXCL12-dependent manner and enhance tumor cell invasion via matrix-metalloproteinase (MMP) activity. Together, our data show that CD26+ and CD26- NFs transform into distinct CAF subpopulations in breast cancer.

12 May 2026 in Nature Communications
Verified
Journal Article
Open access
LDLounes Djerroudi
Lounes Djerroudi
RMRana Mhaidly
Rana Mhaidly
YKYann Kieffer
Yann Kieffer
IDIsabelle Damei
Isabelle Damei
HCHugo Croizer
Hugo Croizer
FMFatima Mechta-Grigoriou
Fatima Mechta-Grigoriou
Invasive lobular breast carcinoma (ILC) shows specific stromal features, and a high tumor-infiltrating lymphocyte (TIL) content being associated with poor patient prognosis. Here, we reveal the underlying mechanism by performing single-cell analysis, immunohistochemistry, deconvolution of bulk RNA-sequencing in a large female ILC series and functional assays. We show that E-cadherin (CDH1)-loss in breast cancer cells prevents differentiation of FAP+ inflammatory cancer-associated fibroblasts (iCAF) into FAP+ myofibroblastic CAF, leading to iCAF accumulation in ILC. In turn, FAP+ iCAF attract TILs into the tumor center, shaping their spatial organization. Subsequently, CDH1-inactivated ILC cancer cells promote immune escape through a lack of retention and activation of ITGAE-expressing resident memory CD8 + T lymphocytes (TRM). Hence, our study uncovers reciprocal interactions between CDH1-inactivated cancer cells, FAP+ iCAF and CD8 + TRM, providing insights into the ILC stromal reaction and revealing why and how TILs are associated with poor prognosis in ILC patients, a mechanism generalizable to other CDH1-inactivated cancer types.